Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Medtech Tags
  5. Medtech

Medtech

Evaluate

Thumbnail
July 10, 2023

More, but slower, medtech approvals

If the second half maintains the pace, 2023 could see the most device approvals for a decade.

Thumbnail
July 07, 2023

Coloplast hooks fish skin tech group for $1.2bn

Article image
Vantage logo
March 22, 2023

Roche and Lilly Eapp into Alzheimer’s testing

Article image
Vantage logo
March 20, 2023

Pear sets out its stall for potential sale

Article image
Vantage logo
March 15, 2023

Illumina investors give long reads short shrift

Article image
Vantage logo
March 10, 2023

Bye, robot – J&J, Vicarious and Titan downsize

Article image
Vantage logo
March 07, 2023

ACC 2023 – the market tries to take Medtronic’s pulse

Being first does not always mean a clear win.

Article image
Vantage logo
March 02, 2023

CVRx awaits a regulatory verdict

Article image
Vantage logo
February 10, 2023

Seven plus eight makes six for Globus

The purchase of Nuvasive for $3.1bn is the biggest ortho deal for some time – and integration will be tough.

Article image
Vantage logo
February 10, 2023

Allurion feels the Spac allure

Article image
Vantage logo
February 09, 2023

Abbott goes peripheral for $890m

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up